TFEB and familial dilated cardiomyopathy: Doxorubicin inhibits the expression of transcription factor EB, so as to reduce the expression of autophagic protein, inhibit autophagic flow, make myocardial cells vulnerable to the toxicity and damage of DOX protein, and increase the susceptibility of DCM (184).